Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047712 | 1.00 | MMP2 (0.44) | MMP2GRIN2BGRIN1GRIN2AGRIN2D | |
| SCHEMBL5505396 | 1.00 | MMP2 (0.44) | MMP2GRIN2BGRIN1GRIN2AGRIN2D | |
| SCHEMBL5974310 | 0.89 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPK1GAA | |
| SCHEMBL5505091 | 0.89 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPK1GAA | |
| SCHEMBL5502026 | 0.89 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPK1GAA | |
| SCHEMBL5133156 | 0.88 | HTR7 (0.42) | GRIN2BGRIN1HTR7MEN1KMT2A | |
| SCHEMBL5133153 | 0.88 | HTR7 (0.42) | GRIN2BGRIN1HTR7MEN1KMT2A | |
| SCHEMBL14300258 | 0.86 | GRIN1 (0.41) | GRIN2BGRIN1HTR7MEN1KMT2A | |
| SCHEMBL5041992 | 0.86 | GRIN1 (0.41) | GRIN2BGRIN1HTR7MEN1KMT2A | |
| SCHEMBL5041768 | 0.86 | GRIN1 (0.41) | GRIN2BGRIN1HTR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | claimed |
| EP-1189886-B1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | claimed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | claimed |
| EP-1332363-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2003-08-06 | — | — | EP | claimed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | claimed |
| EP-1189886-A1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | claimed |
| US-6310213-B1 | GOOD AFFITITY TO THE NMDA RECEPTOR AND THEY ARE THEREFORE USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | claimed |
| WO-2000075109-A1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-14 | — | — | WO | claimed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| EP-1332363-A4 | DETECTION OF NEURODEGENERATIVE DISORDERS | DOUBLE KAY (AU) | 2007-08-29 | — | — | EP | disclosed |
| EP-1189886-B1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-20050260577-A1 | Detection of neurodegenerative disorders | POWMRI LIMITED (AU) | 2005-11-24 | — | — | US | disclosed |
| EP-1136475-B1 | Piperidine and piperazine compounds for use in the treatment of Alzheimer | HOFFMANN LA ROCHE (CH) | 2004-08-18 | — | — | EP | disclosed |
| WO-2002031499-A1 | DETECTION OF NEURODEGENERATIVE DISORDERS | UNISEARCH LIMITED (AU) | 2002-04-18 | — | — | WO | disclosed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | disclosed |
| EP-1189886-A1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-27 | — | — | EP | disclosed |
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6310213-B1 | GOOD AFFITITY TO THE NMDA RECEPTOR AND THEY ARE THEREFORE USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HOFFMANN-LA ROCHE INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2000075109-A1 | ETHANESULFONYL-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037026-A1 | Process for the preparation of ethanesul fonyl-piperidine derivatives | GRIN1, GRIN3A, GRIN2B | MMP2 4551/4885GRIN2B 3/4885GRIN1 1/4885 |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | HAO2, CYP2B6, CBR1 | MMP2 3129/4885GRIN2B 2694/4885GRIN1 3691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.